Research Lab Results for biomarkers
-
Chirag Parikh Lab
Lab WebsiteDr. Parikh's research focuses on the translation and validation of novel biomarkers for the dia...gnosis and prognosis of acute kidney injury. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh's research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. He has assembled multicenter longitudinal prospective cohorts for translational research studies across several clinical settings of acute kidney injury and chronic kidney disease for the efficient translation of novel biomarkers.
Research Areas: acute kidney injury, biomarkers, Kidney Transplantation, chronic kidney disease
His research is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, the development of clinical studies, and the design of clinical trials. Dr. Parikh's studies have refined the clinical definition in perioperative acute kidney injury and hepatorenal syndrome, developed strategies to reduce kidney discard in deceased donor transplantation, and advanced regulatory approvals of kidney injury biomarkers. He has also developed biomarkers to identify rapid progressors of early diabetic kidney disease before derangements in serum creatinine. Dr. Parikh's research goal is to translate our understanding of pathophysiological mechanisms into clinical practice and improve the outcomes in patients with kidney disease.
Dr. Parikh has also been the recipient of numerous honors, including the 2017 Young Investigator Award from the American Society of Nephrology.
view more -
Christopher A. Ross Lab
Lab WebsiteDr. Ross and his research team have focused on Huntington's disease and Parkinson's disease, an...d now are using insights from these disorders to approach more complex diseases such as schizophrenia and bipolar disorder. They use biophysical and biochemical techniques, cell models, and transgenic mouse models to understand disease processes, and to provide targets for development of rational therapeutics. These then can provide a basis for developing small molecule interventions, which can be used both as probes to study biology, and if they have favorable drug-like properties, for potential therapeutic development. We have used two strategies for identifying lead compounds. The first is the traditional path of identification of specific molecular targets, such as enzymes like the LRRK2 kinase of Parkinson’s disease. Once structure is known, computational approaches or fragment based lead discovery, in collaboration, can be used. The second is to conduct phenotypic screens using cell models, or in a collaboration, natural products in a yeast model. Once a lead compound is identified, we use cell models for initial tests of compounds, then generate analogs, and take compounds that look promising to preclinical therapeutic studies in animal models. The ultimate goal is to develop therapeutic strategies that can be brought to human clinical trials, and we have pioneered in developing biomarkers and genetic testing for developing strategies. view more
Research Areas: psychiatric disorders -
Clinical Laboratory and Biomarkers Core
Lab WebsiteThe Clinical Laboratory and Biomarkers Cores will coordinate access to laboratory expertise, te...sting, training, specimen repositories and Good Clinical Laboratory Practices (GCLP). The goals of this core are to assure that all JHU HIV investigators have access to and utilize appropriate, validated and, where applicable, certified laboratory assays. The core will also maintain a biomarker specimen repository for storage cataloguing and utilization of biological specimens. view more
Research Areas: virology, immunology, biomarkers, HIV, pathogenesis -
Eberhart, Rodriguez and Raabe Lab
Lab WebsiteUtilizing a combination of tissue-based, cell-based, and molecular approaches, our research goa...ls focus on abnormal telomere biology as it relates to cancer initiation and tumor progression, with a particular interest in the Alternative Lengthening of Telomeres (ALT) phenotype. In addition, our laboratories focus on cancer biomarker discovery and validation with the ultimate aim to utilize these novel tissue-based biomarkers to improve individualized prevention, detection, and treatment strategies. view more
Research Areas: cancer therapies, preventing cancer metastasis, cancer, cancer biomarkers -
Eberhart, Rodriguez and Raabe Lab
Lab WebsiteUtilizing a combination of tissue-based, cell-based, and molecular approaches, our research goa...ls focus on abnormal telomere biology as it relates to cancer initiation and tumor progression, with a particular interest in the Alternative Lengthening of Telomeres (ALT) phenotype. In addition, our laboratories focus on cancer biomarker discovery and validation with the ultimate aim to utilize these novel tissue-based biomarkers to improve individualized prevention, detection, and treatment strategies.
Research Areas: stem cells, eye tumor, tumor cell metastasis, brain tumor
view more -
Elizabeth Selvin Lab
The Elizabeth Selvin Lab examines the intersection of epidemiology, clinical policy and public ...health policy. One of our key goals is to use the findings of epidemiologic research to inform the screening, diagnosis and treatment of diabetes, cardiovascular disease and kidney disease. Much of our work looks at biomarkers and diagnostics related to diabetes and diabetes complications. Our findings — linking hemoglobin A1c (HbA1c) to diabetic complications and identifying the role of A1c in diabetes diagnosis — have influenced clinical practice guidelines. view more
Research Areas: epidemiology, biomarkers, kidney diseases, obesity, diabetes, health care policy, cardiovascular diseases -
Eugene Shenderov Laboratory
Lab WebsiteThe Shenderov Lab focuses on the elucidation of the mechanisms of immune response and resistanc...e to immunotherapy in Prostate Cancer. This has led to clinical and basic research investigating the presumptive checkpoint inhibitor B7-H3.
Research Areas: Cancer Immunotherapy, tumor antigens, prostate cancer, Immunogenomics, artificial intelligence, Spatialomics, B7-H3
In pursuit of understanding biomarkers or resistance and response, and regulatory molecules of immune response, we utilize artificial intelligence, immunogenomics, and spatial proteomics and transcriptomics in the laboratory and at the bedside using clinical trial correlative samples. view more -
Franck Housseau Lab
The Franck Housseau Lab focuses on the role of the microbiome in colorectal tumorigenesis and o...n developing a better understanding of the tumor immune microenvironment. The lab is currently working to define the biomarkers of a pre-existing antitumor immune response in metastatic colorectal cancer to define a population of patients eligible for checkpoint blockade therapies. view more
Research Areas: microbiology, tumor immunology, microbiome, colorectal cancer, cancer, colon cancer, tumor microenvironment, immunotherapy -
GI Biomarkers Laboratory
The GI Biomarkers Laboratory studies gastrointestinal cancer and pre-cancer biogenesis and biom...arkers. The lab is led by Dr. Stephen Meltzer, who is known for his research in the molecular pathobiology of gastrointestinal malignancy and premalignancy. Research in the lab has led to several groundbreaking genomic, epigenomic and bioinformatic studies of esophageal and colonic neoplasms, shifting the gastrointestinal research paradaigm toward genome-wide approaches. view more
Research Areas: gastrointestinal system, translational research in Barrett’s esophagus-associated neoplastic progression, Molecular pathophysiology, biomarkers, cancer, epigenetics, genomics, bioinformatics, biogenesis -
GI Early Detection Biomarkers Lab
Dr. Meltzer is an internationally renowned leader in the molecular pathobiology of gastrointest...inal malignancy and premalignancy. He invented molecular methods to detect loss of heterozygosity in tiny biopsies, triggering an avalanche of research on precancerous lesions. He was the first to comprehensively study coding region microsatellite instability, leading to the identification of several important tumor suppressor genes. He performed several groundbreaking genomic, epigenomic and bioinformatic studies of esophageal and colonic neoplasms, shifting the GI research paradigm toward genome-wide approaches. He directed an ambitious nationwide validation study of DNA methylation-based biomarkers for the prediction of neoplastic progression in Barrett’s esophagus.
Research Areas: gastrointestinal cancer, gastrointestinal
Dr. Meltzer founded and led the Aerodigestive Cancer and Biomarker Interdisciplinary Programs at the University of Maryland, also becoming associate director for core sciences at that school’s Cancer Center. He currently holds an endowed professorship and is the director of GI biomarker research at Johns Hopkins.
The laboratory group focuses its efforts on the molecular genetics of gastrointestinal cancers and premalignant lesions, as well as on translational research to improve early detection, prognostic evaluation, and treatment of these conditions. Below, some examples of this work are described. view more